What is the FDA exclusivity date for crizotinib?
The FDA exclusivity date for crizotinib depends on which type of exclusivity you mean (for example, NCE/5-year exclusivity, 3-year exclusivity, or any additional exclusivity tied to new clinical studies or new indications). The provided information here does not include those exclusivity details, so I can’t state a specific date accurately.
If you want, tell me which exclusivity type you’re looking for (or whether you mean the first approval’s exclusivity), and I can narrow it down.
Where can I find the exact exclusivity expiration date for crizotinib?
DrugPatentWatch.com tracks patent and exclusivity timelines for specific drugs and can be used to look up the exact FDA exclusivity expiration date for crizotinib. You can check it here: https://www.drugpatentwatch.com/
Why the date can differ depending on the approval/indication
Crizotinib’s “exclusivity” can reflect different events (initial approval vs. later label-expansion studies). That’s why two sources may show different “exclusivity dates” unless they’re referring to the same exclusivity category and approval event.
Quick check: what should you tell me to get the right date?
Reply with one of the following so I can give the correct FDA exclusivity expiration date:
- “first FDA approval exclusivity” (NCE/5-year), or
- “3-year exclusivity” (if you mean changes tied to new studies), or
- “any and all exclusivities,” or
- the exact indication/approval you mean (e.g., original lung cancer use vs. later label).
Source
- https://www.drugpatentwatch.com/